{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:21:59Z","timestamp":1790011319718,"version":"4.0.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA215802"],"award-info":[{"award-number":["R01CA215802"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK117183"],"award-info":[{"award-number":["R01DK117183"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.kint.2021.08.022","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T22:08:29Z","timestamp":1631657309000},"page":"1214-1226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition"],"prefix":"10.1016","volume":"100","author":[{"given":"Yuntao","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijay","family":"Bisunke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josie A.","family":"Silvaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Balzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Prosek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Cianciolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharyn D.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Sparreboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenar D.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Susztak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Bajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navjot Singh","family":"Pabla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2021.08.022_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0140-6736(20)30540-7","article-title":"The link between kidney disease and cancer: complications and treatment","volume":"396","author":"Malyszko","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2021.08.022_bib2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0140-6736(11)61454-2","article-title":"Acute kidney injury","volume":"380","author":"Bellomo","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2021.08.022_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.ajkd.2013.07.008","article-title":"Reduced estimated GFR and cancer mortality","volume":"63","author":"Iff","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2021.08.022_bib4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0002-9343(57)90224-3","article-title":"A\u00a0syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone","volume":"23","author":"Schwartz","year":"1957","journal-title":"Am J Med"},{"key":"10.1016\/j.kint.2021.08.022_bib5","doi-asserted-by":"crossref","first-page":"A15","DOI":"10.1053\/j.ajkd.2019.09.005","article-title":"Hyponatremia in a patient with cancer","volume":"75","author":"Uppal","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2021.08.022_bib6","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMra1613984","article-title":"Acute kidney injury in patients with cancer","volume":"376","author":"Rosner","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.08.022_bib7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.semnephrol.2010.09.003","article-title":"Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group","volume":"30","author":"Launay-Vacher","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2021.08.022_bib8","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.08.022_bib9","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.kint.2016.06.027","article-title":"Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System","volume":"90","author":"Jhaveri","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.08.022_bib10","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.03140312","article-title":"Onco-nephrology: AKI in the cancer patient","volume":"7","author":"Lam","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.08.022_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1681\/ASN.2012070690","article-title":"Onconephrology: the latest frontier in the war against kidney disease","volume":"24","author":"Salahudeen","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.08.022_bib12","first-page":"47","article-title":"Onconephrology: the intersections between the kidney and cancer","volume":"71","author":"Rosner","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.kint.2021.08.022_bib13","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2215\/CJN.03770412","article-title":"Onco-nephrology: glomerular diseases with cancer","volume":"7","author":"Cambier","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.08.022_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","article-title":"Targeting alterations in the RAF\u2013MEK pathway","volume":"9","author":"Yaeger","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.kint.2021.08.022_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrc3760","article-title":"Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond","volume":"14","author":"Holderfield","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.kint.2021.08.022_bib16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.kint.2021.08.022_bib17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nrd3579","article-title":"Vemurafenib","volume":"10","author":"Flaherty","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.kint.2021.08.022_bib18","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: the first drug approved for BRAF -mutant cancer","volume":"11","author":"Bollag","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.kint.2021.08.022_bib19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2021.08.022_bib20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","article-title":"Analysis of dermatologic events in vemurafenib-treated patients with melanoma","volume":"18","author":"Lacouture","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.kint.2021.08.022_bib21","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.kint.2021.08.022_bib22","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2015.1713","article-title":"Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib","volume":"1","author":"Jhaveri","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.kint.2021.08.022_bib23","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/jdv.12322","article-title":"Vemurafenib significantly decreases glomerular filtration rate","volume":"28","author":"Uthurriague","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.kint.2021.08.022_bib24","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/bjd.12555","article-title":"Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas","volume":"169","author":"Regnier-Rosencher","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.kint.2021.08.022_bib25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00280-016-3086-7","article-title":"New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma","volume":"78","author":"Teuma","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.kint.2021.08.022_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149873","article-title":"Mechanisms underpinning increased plasma creatinine levels in patients receiving vemurafenib for advanced melanoma","volume":"11","author":"Hurabielle","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2021.08.022_bib27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1073\/pnas.1104767109","article-title":"Checkpoint kinase 1 (Chk1)-short is a splice variant and endogenous inhibitor of Chk1 that regulates cell cycle and DNA damage checkpoints","volume":"109","author":"Pabla","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2021.08.022_bib28","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/s41467-020-15638-6","article-title":"A\u00a0kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2021.08.022_bib29","doi-asserted-by":"crossref","first-page":"10880","DOI":"10.1038\/ncomms10880","article-title":"A\u00a0phosphotyrosine switch regulates organic cation transporters","volume":"7","author":"Sprowl","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2021.08.022_bib30","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1073\/pnas.1424313112","article-title":"Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4\/6 and OCT2 functions","volume":"112","author":"Pabla","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2021.08.022_bib31","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.7150\/thno.22641","article-title":"Enhancement of cancer-specific protoporphyrin IX fluorescence by targeting oncogenic Ras\/MEK pathway","volume":"8","author":"Yoshioka","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.kint.2021.08.022_bib32","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/j.jacc.2013.02.012","article-title":"Heme levels are increased in human failing hearts","volume":"61","author":"Khechaduri","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2021.08.022_bib33","doi-asserted-by":"crossref","first-page":"113939","DOI":"10.1016\/j.bcp.2020.113939","article-title":"Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms","volume":"177","author":"Kim","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.kint.2021.08.022_bib34","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","article-title":"Cisplatin nephrotoxicity: mechanisms and renoprotective strategies","volume":"73","author":"Pabla","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.08.022_bib35","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.kint.2021.08.022_bib36","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/0008-5472.CAN-11-2941","article-title":"Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer","volume":"72","author":"Yang","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.kint.2021.08.022_bib37","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1074\/jbc.273.7.4135","article-title":"Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury","volume":"273","author":"Ichimura","year":"1998","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2021.08.022_bib38","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.celrep.2015.07.034","article-title":"Sox9 activation highlights a cellular pathway of renal repair in the acutely injured mammalian kidney","volume":"12","author":"Kumar","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.kint.2021.08.022_bib39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000049032","article-title":"The inflammatory cascade in acute ischemic renal failure","volume":"90","author":"Okusa","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2021.08.022_bib40","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2174\/138945009789753174","article-title":"Immune mechanisms and novel pharmacological therapies of acute kidney injury","volume":"10","author":"Bajwa","year":"2009","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.kint.2021.08.022_bib41","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1172\/JCI200215606","article-title":"TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity","volume":"110","author":"Ramesh","year":"2002","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.08.022_bib42","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3389\/fimmu.2020.01278","article-title":"FTY720 regulates mitochondria biogenesis in dendritic cells to prevent kidney ischemic reperfusion injury","volume":"11","author":"Rousselle","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2021.08.022_bib43","doi-asserted-by":"crossref","first-page":"16328","DOI":"10.1074\/jbc.RA120.015110","article-title":"SOX9 promotes stress-responsive transcription of VGF nerve growth factor inducible gene in renal tubular epithelial cells","volume":"295","author":"Kim","year":"2020","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2021.08.022_bib44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/jnr.20703","article-title":"Forebrain-specific knockout of B-raf kinase leads to deficits in hippocampal long-term potentiation, learning, and memory","volume":"83","author":"Chen","year":"2006","journal-title":"J\u00a0Neurosci Res"},{"key":"10.1016\/j.kint.2021.08.022_bib45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1172\/JCI0215518","article-title":"Evidence that fibroblasts derive from epithelium during tissue fibrosis","volume":"110","author":"Iwano","year":"2002","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.08.022_bib46","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1172\/JCI76094","article-title":"Targeting cancer with kinase inhibitors","volume":"125","author":"Gross","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.08.022_bib47","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.kint.2021.08.022_bib48","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrc2787","article-title":"Targeting the cancer kinome through polypharmacology","volume":"10","author":"Knight","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.kint.2021.08.022_bib49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nchembio.332","article-title":"A\u00a0chemical and phosphoproteomic characterization of dasatinib action in lung cancer","volume":"6","author":"Li","year":"2010","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.kint.2021.08.022_bib50","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00280-017-3300-2","article-title":"Adjunction of a MEK inhibitor to vemurafenib in the treatment of metastatic melanoma results in a 60% reduction of acute kidney injury","volume":"79","author":"Teuma","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.kint.2021.08.022_bib51","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies","volume":"23","author":"Liston","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.kint.2021.08.022_bib52","doi-asserted-by":"crossref","first-page":"1255784","DOI":"10.1126\/science.1255784","article-title":"Tracking cancer drugs in living cells by thermal profiling of the proteome","volume":"346","author":"Savitski","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.kint.2021.08.022_bib53","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1021\/acschembio.5b01063","article-title":"Chemical proteomics reveals ferrochelatase as a common off-target of kinase inhibitors","volume":"11","author":"Klaeger","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.kint.2021.08.022_bib54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1172\/JCI1347","article-title":"Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation","volume":"102","author":"Bloomer","year":"1998","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.08.022_bib55","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0002-9629(15)40628-7","article-title":"Cell biology of heme","volume":"318","author":"Ponka","year":"1999","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.kint.2021.08.022_bib56","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.3390\/ijms22105386","article-title":"Rapamycin alternatively modifies mitochondrial dynamics in dendritic cells to reduce kidney ischemic reperfusion injury","volume":"22","author":"Namwanje","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2021.08.022_bib57","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cmet.2020.11.011","article-title":"The nuclear receptor ESRRA protects from kidney disease by coupling metabolism and differentiation","volume":"33","author":"Dhillon","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.kint.2021.08.022_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.113","article-title":"A\u00a0single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma","volume":"3","author":"Goldinger","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.kint.2021.08.022_bib59","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.kint.2021.08.022_bib60","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1172\/JCI45161","article-title":"Cellular pathophysiology of ischemic acute kidney injury","volume":"121","author":"Bonventre","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.08.022_bib61","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrneph.2017.107","article-title":"Mitochondrial energetics in the kidney","volume":"13","author":"Bhargava","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2021.08.022_bib62","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/sj.ki.5002312","article-title":"The endothelial cell in ischemic acute kidney injury: implications for acute and chronic function","volume":"72","author":"Basile","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.08.022_bib63","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000477830","article-title":"Renal oxygenation and hemodynamics in kidney injury","volume":"137","author":"Bullen","year":"2017","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2021.08.022_bib64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/HYPERTENSIONAHA.116.07618","article-title":"Mechanisms of hypertension and renal injury during vascular endothelial growth factor signaling inhibition","volume":"68","author":"van den Meiracker","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2021.08.022_bib65","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.chembiol.2017.11.006","article-title":"GDC-0879, a BRAFV600E inhibitor, protects kidney podocytes from death","volume":"25","author":"Sieber","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.kint.2021.08.022_bib66","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.chembiol.2018.01.018","article-title":"Screening drugs for kidney disease: targeting the podocyte","volume":"25","author":"Bryer","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.kint.2021.08.022_bib67","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1681\/ASN.2006080894","article-title":"Physiology and pathophysiology of heme: implications for kidney disease","volume":"18","author":"Tracz","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.08.022_bib68","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.semnephrol.2016.01.003","article-title":"Targeting iron homeostasis in acute kidney injury","volume":"36","author":"Walker","year":"2016","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2021.08.022_bib69","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.semnephrol.2018.10.006","article-title":"Iron homeostasis in healthy kidney and its role in acute kidney injury","volume":"39","author":"Scindia","year":"2019","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2021.08.022_bib70","first-page":"336","article-title":"Regulation of porphyrin and heme metabolism in the kidney","volume":"25","author":"Woods","year":"1988","journal-title":"Semin Hematol"},{"key":"10.1016\/j.kint.2021.08.022_bib71","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1038\/s41467-020-18607-1","article-title":"MFSD7C switches mitochondrial ATP synthesis to thermogenesis in response to heme","volume":"11","author":"Li","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2021.08.022_bib72","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10637-016-0379-y","article-title":"The renal effects of ALK inhibitors","volume":"34","author":"Izzedine","year":"2016","journal-title":"Invest New Drugs"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821008553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821008553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T13:05:03Z","timestamp":1769173503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253821008553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0085253821008553"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2021.08.022","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2021.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}